Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

L-021

Supelco

Lorazepam glucuronide solution

100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C21H18Cl2N2O8
Número CAS:
Peso molecular:
497.28
Número MDL:
Código UNSPSC:
41116107
ID de substância PubChem:
NACRES:
NA.24
Preço e disponibilidade não estão disponíveis no momento.

grau

certified reference material

Formulário

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentração

100 μg/mL in acetonitrile: water (1:1)

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

clinical testing

Formato

single component solution

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3Cl)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1

chave InChI

IWOJSSFCRQKNKN-IFBJMGMISA-N

Descrição geral

Lorazepam glucuronide is a primary urinary metabolite of lorazepam, a benzodiazepine often prescribed for treatment of anxiety disorders. This Certified Spiking Solution® is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogramas

FlameExclamation mark

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

55.4 °F - closed cup

Ponto de fulgor (°C)

13 °C - closed cup


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

G Morrison et al.
Clinical pharmacology and therapeutics, 35(5), 646-652 (1984-05-01)
The effect of renal disease on lorazepam kinetics was assessed in three groups: six normal subjects, six patients with renal impairment, and four functionally anephric patients. Subjects received single 1.5- or 3-mg intravenous and oral doses; eight subjects (four normal
L L von Moltke et al.
Biopharmaceutics & drug disposition, 14(2), 119-130 (1993-03-01)
The effect of probenecid on glucuronidation of acetaminophen and lorazepam in hepatic microsomes from various species was studied to see if in vitro results were consistent with previous in vivo observations. Mouse, rat, and human microsomes were incubated with acetaminophen
Olga Papini et al.
Journal of pharmaceutical and biomedical analysis, 40(2), 397-403 (2005-09-07)
The present study investigates the kinetic disposition with focus on the racemization, glucuronidation capacity and the transplacental transfer of lorazepam in term parturients during labor. The study was conducted on 10 healthy parturients aged 18-37 years with a gestational age
Eleonora L Swart et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 45(2), 360-371 (2005-02-03)
The objective is to study the population pharmacokinetics of lorazepam and midazolam in critically ill patients with acute renal failure who are treated with continuous venovenous hemofiltration (CVVH). Twenty critically ill patients with acute renal failure on CVVH therapy were
R Verbeeck et al.
British journal of clinical pharmacology, 3(6), 1033-1039 (1976-12-01)
To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (CC(r) : less than 2 ml/min)

Protocolos

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica